Centre Hospitalier Universitaire De Toulouse
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
At Centre Hospitalier Universitaire De Toulouse, research in hematologic cancers focuses on aggressive and hard-to-treat diseases such as relapsed or refractory FLT3-mutated acute myeloid leukemia and Richter’s syndrome. These studies are designed to assess new treatment combinations and improve response rates in patients with limited options.
- Testing new combination therapies for acute myeloid leukemia
- Evaluating treatment effectiveness in Richter’s syndrome
- Exploring better ways to control advanced blood cancers
The work in this area aims to strengthen treatment outcomes while also examining how well patients tolerate these approaches in real-world clinical settings.
Nervous System Diseases
The Gérontopôle is actively involved in studies on Alzheimer’s disease, early Alzheimer’s disease, and mild cognitive impairment due to Alzheimer’s disease. This research is centered on improving symptom control, slowing cognitive decline, and finding more effective ways to detect and monitor disease progression.
- Assessing therapies for early Alzheimer’s disease
- Studying treatment options for mild cognitive impairment linked to Alzheimer’s disease
- Measuring changes in memory and daily functioning over time
Several trials at the site are focused on testing whether new neurology treatments can preserve cognition and function in older adults at different stages of disease.
Respiratory Tract Diseases
Clinical research in respiratory medicine at this hospital includes studies in interstitial lung disease, with attention to progressive forms that involve inflammation. The main goal is to evaluate whether new or repurposed therapies can improve lung function and help slow disease worsening.
- Evaluating treatment benefit in interstitial lung disease
- Studying approaches for progressive lung disease with inflammatory features
- Measuring changes in breathing capacity and overall respiratory health
This area of research supports better management options for patients living with chronic and progressive lung conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 26 therapeutic areas and 15 of 298 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 296 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 54 by active trials.
lock +53 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +28 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Toulouse
lock Showing 1 of 166 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome | Bayer AG | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 298 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 12 | Unknown | 2017-03-15 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.